MwanzoGNLX • NASDAQ
add
Genelux Corp
Bei iliyotangulia
$ 2.42
Bei za siku
$ 2.43 - $ 2.72
Bei za mwaka
$ 1.60 - $ 5.89
Thamani ya kampuni katika soko
99.45M USD
Wastani wa hisa zilizouzwa
elfu 192.42
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 0.00 | — |
Matumizi ya uendeshaji wa biashara | 9.75M | 39.24% |
Mapato halisi | -8.98M | -32.64% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.26 | -4.00% |
EBITDA | -9.69M | -40.33% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 30.90M | 33.22% |
Jumla ya mali | 34.72M | 24.46% |
Jumla ya dhima | 8.44M | 0.26% |
Jumla ya hisa | 26.27M | — |
hisa zilizosalia | 34.17M | — |
Uwiano wa bei na thamani | 3.15 | — |
Faida inayotokana na mali | -65.00% | — |
Faida inayotokana mtaji | -77.03% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -8.98M | -32.64% |
Pesa kutokana na shughuli | -4.30M | 37.74% |
Pesa kutokana na uwekezaji | 6.67M | 147.87% |
Pesa kutokana na ufadhili | elfu 91.00 | -77.31% |
Mabadiliko halisi ya pesa taslimu | 2.46M | 112.04% |
Mtiririko huru wa pesa | -1.37M | 70.63% |
Kuhusu
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Ilianzishwa
2001
Makao Makuu
Tovuti
Wafanyakazi
24
